At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Abatacept 30mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Randomized, Placebo-Controlled, Double Blind, Parallel Group Study to Evaluate the Tolerability of a Single Dose of Abatacept 30 mg/kg Via Intravenous Infusion in Chinese SLE Subjects With Lupus Nephritis
In Brief
A Phase 1 clinical trial evaluating Placebo and Abatacept for Lupus Nephritis. Completed, enrolled 13 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus (SLE)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLupus Nephritis
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartAug 2008
Primary CompletionJan 2009
Study CompletionJul 2011
TodayJul 2026
First PostedJun 26, 2008
Enrollment StartAug 1, 2008
Primary CompletionJan 1, 2009
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.0 years ago
Interventions
Placebodrug
Infusion, Intravenous, single dose, Day 1
Abataceptdrug
Infusion, Intravenous, 30mg/kg, single dose, Day 1
Abataceptdrug
Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study